Table 3.
Treatment-emergent adverse events regardless of relationship to study drugs
| Adverse event | Grade 1–2 | Grade 3–4 | Grade 5 |
|---|---|---|---|
| Dry skin | 21 | 1 | |
| Nausea | 13 | 2 | |
| Fatigue | 11 | 2 | |
| Diarrhoea | 8 | 0 | |
| Decreased appetite | 5 | 0 | |
| Headache | 5 | 0 | |
| Lethargy | 5 | 0 | |
| Vomiting | 4 | 0 | |
| Rash | 3 | 1 | |
| Cough | 3 | 0 | |
| Dizziness | 3 | 1 | |
| Arthralgia | 3 | 0 | |
| Insomnia | 3 | 0 | |
| Sepsis | 0 | 1 | |
| Haemoglobin | 0 | 1 | |
| Urinary tract infection | 0 | 1 | |
| Breast ulceration | 0 | 1 | |
| Gamma GT increase | 0 | 2 | |
| Blurred vision | 0 | 1 | |
| Bone pain | 0 | 1 | |
| Pleurodesis | 0 | 1 | |
| Pneumonia | 0 | 0 | 1 |
Grades 1 and 2 with an incidence of 10% of study population and all grade 3–5 toxicities